scholarly journals Blood pressure control in italian nephroly clinics. results of thin-study (treatment of hypertension in italian nephrology clinics)

2004 ◽  
Vol 17 (5) ◽  
pp. S180
Author(s):  
A DEBLASIO
Keyword(s):  
Blood Pressure ◽  
Blood Pressure Control ◽  
Pressure Control ◽  
Treatment Of Hypertension

scholarly journals Electronic Monitoring of Adherence, Treatment of Hypertension, and Blood Pressure Control

2012 ◽  
Vol 25 (1) ◽  
pp. 54-59 ◽  
Author(s):  
H. A. W. v. Onzenoort ◽  
W. J. Verberk ◽  
A. A. Kroon ◽  
A. G. H. Kessels ◽  
C. Neef ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Blood Pressure Control ◽  
Electronic Monitoring ◽  
Pressure Control ◽  
Treatment Of Hypertension

Controlling Blood Pressure without Drugs – Developing New Strategies

2010 ◽  
Vol 6 (2) ◽  
pp. 18
Author(s):  
Markus P Schlaich ◽  
Murray D Esler ◽  
◽  
Keyword(s):  
Blood Pressure ◽  
Blood Pressure Control ◽  
Pressure Control ◽  
Therapeutic Strategies ◽  
Novel Device ◽  
Major Player ◽  
Treatment Of Hypertension ◽  
Sympathetic Nervous ◽  
Optimal Blood Pressure ◽  
New Strategies

Non-optimal blood pressure is the leading cause of death globally, and each year is responsible for seven million deaths. Current therapeutic strategies for hypertension are mainly based on lifestyle interventions and pharmacological approaches, but rates of blood pressure control remain unsatisfactory and additional options are required. In this context, novel device-based approaches specifically targeting the sympathetic nervous system as a major player in blood pressure control have recently been tested clinically with promising results. Device-based approaches may provide additional and more effective treatment of hypertension and its adverse consequences in the future.

Controlling Blood Pressure without Drugs – Developing New Strategies

2011 ◽  
Vol 3 (1) ◽  
pp. 37
Author(s):  
Markus P Schlaich ◽  
Murray D Esler ◽  
◽  
Keyword(s):  
Blood Pressure ◽  
Blood Pressure Control ◽  
Pressure Control ◽  
Therapeutic Strategies ◽  
Novel Device ◽  
Major Player ◽  
Treatment Of Hypertension ◽  
Sympathetic Nervous ◽  
Optimal Blood Pressure ◽  
New Strategies

Non-optimal blood pressure is the leading cause of cardiovascular-related death worldwide, and each year is responsible for seven million deaths. Current therapeutic strategies for hypertension are mainly based on lifestyle interventions and pharmacological approaches, but rates of blood pressure control remain unsatisfactory and additional options are required. In this context, novel device-based approaches specifically targeting the sympathetic nervous system as a major player in blood pressure control have recently been tested clinically with promising results. Device-based approaches may provide additional and more effective treatment of hypertension and its adverse consequences in the future.

Treatment of Hypertension in Middle-Aged Men: A Feasibility Study in a Community

1976 ◽  
Vol 51 (s3) ◽  
pp. 597s-599s
Author(s):  
H. Åberg ◽  
H. Hedstrand
Keyword(s):  
Blood Pressure ◽  
Diastolic Blood Pressure ◽  
Feasibility Study ◽  
Blood Pressure Control ◽  
Blood Pressure Reduction ◽  
Pressure Control ◽  
Health Examination ◽  
Pressure Reduction ◽  
Hypertension Clinic ◽  
Treatment Of Hypertension

1. In a health examination survey of 2322 men, aged 49–50 years, the prevalence of hypertension was 7·5%. All men with a supine diastolic blood pressure ≥ 105 mmHg were invited to a hypertension clinic. 2. Two years' treatment in eighty-six men achieved a blood pressure reduction of 31/16 mmHg, which was maintained for a 4 years period and considered satisfactory in 80% of the subjects. Propranolol was used in more than 80% of the cases. 3. The study indicates that it is possible to obtain acceptable blood pressure control in the community.

Aliskiren for the Treatment of Hypertension: An Update

2009 ◽  
Vol 1 ◽  
pp. CMT.S1991
Author(s):  
S Lam ◽  
S Saxena ◽  
LO Macina ◽  
PE Lester
Keyword(s):  
Blood Pressure ◽  
Blood Pressure Control ◽  
Disease Risk ◽  
Angiotensin Receptor Blockers ◽  
Blood Pressure Reduction ◽  
Antihypertensive Agents ◽  
Pressure Control ◽  
Pressure Reduction ◽  
Efficacy And Safety ◽  
Treatment Of Hypertension

Hypertension can lead to significant morbidity and mortality, and requires lifestyle modifications with or without drug therapy to achieve target blood pressure control. Various classes of anti-hypertensive medications are available to healthcare providers. Choice of medications is based not only on efficacy but also tolerability and cost. Aliskiren is the first drug of a new class of agents known as renin inhibitors. It is approved by the U.S. Food and Drug Administration (FDA) as monotherapy or combination therapy with other antihypertensive agents to optimize blood pressure control. Its efficacy in blood pressure reduction is superior to placebo and comparable to angiotensin receptor blockers, hydrochlorothiazide, angiotensin-converting-enzyme inhibitors and atenolol. It also offers additional blood pressure reduction when used in combination of other agents. Recently, a study demonstrated its efficacy and safety in the elderly, and a study suggested its renoprotective effects in patient who were already taking losartan. More clinical studies are awaited to assess its potential for cardiovascular disease risk reduction. This paper reviews the pharmacology, efficacy and safety of aliskiren for the treatment of hypertension.

Rationale and design of Faith-based Approaches in the Treatment of Hypertension (FAITH), a lifestyle intervention targeting blood pressure control among black church members

2014 ◽  
Vol 167 (3) ◽  
pp. 301-307 ◽  
Author(s):  
Kristie J. Lancaster ◽  
Antoinette M. Schoenthaler ◽  
Sara A. Midberry ◽  
Sheldon O. Watts ◽  
Matthew R. Nulty ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Lifestyle Intervention ◽  
Blood Pressure Control ◽  
Black Church ◽  
Pressure Control ◽  
Church Members ◽  
Faith Based ◽  
Treatment Of Hypertension

Trasidrex (A Fixed Combination of Slow Trasicor 160mg and Navidrex 0.25mg) in the Treatment of Hypertension: A Multicentre Clinical Trial in General Practice

1978 ◽  
Vol 6 (6) ◽  
pp. 494-498 ◽  
Author(s):  
A F Ebbutt ◽  
R W Elsdon-Dew ◽  
J E Murphy
Keyword(s):  
Blood Pressure ◽  
Clinical Trial ◽  
General Practice ◽  
Side Effects ◽  
Blood Pressure Control ◽  
Fixed Combination ◽  
Pressure Control ◽  
Combination Tablet ◽  
Multicentre Clinical Trial ◽  
Treatment Of Hypertension

Sixty-two patients with hypertension who were treated with a free combination of Slow Trasicor or Trasicor and Navidrex K were transferred to a fixed combination tablet, Trasidrex (slow oxprenolol 160 mg + cyclopenthiazide 0.25 mg). Blood pressure control was marginally improved and there was no increase in side-effects.

Sign in / Sign up

Export Citation Format

Share Document